

08-23-04

Express Mail No. EV 462 737 763 US
Attorney Docket UCA



## THEODIVIATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e)

First Named Inventor PRUSINER, STANLEY B.

Application Number 10/735,140

Confirmation No. 5681

Filing Date December 12, 2003

Group Art Unit 1616

Examiner Name

UCAL-131CON3

Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Title: "SODIUM DODECYL SULFATE COMPOSITIONS FOR INACTIVATING PRIONS"

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. UCAL-131CON3.

By:

Respectfully submitted,

**BOZICEVIC, FIELD & FRANCIS LLP** 

Date:

BOZICEVIC, FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200

Menlo Park, CA 94025 Telephone: (650) 327-3400 Facsimile: (650) 327-3231 Karl Bozicevic, Reg.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are re required to respond to a collection of information unless it contains a valid OMB control number, Complete if Known Substitute for form 1449A/PTO 10//735,140 **Application Number** INFORMATION DISCLOSURE Filing Date December 12, 2003 STATEMENT BY APPLICANT First Named Inventor PRUSINER, STANLEY B. Group Art Unit 1616 (use as many sheets as necessary) Examiner Name 1 Attorney Docket Number UCAL-131CON3 Sheet of

U.S. PATENT DOCUMENTS						
Examin er Initials'	Cite No. <sup>1</sup>	U.S. Pate Number	ent Documents  Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Documents  Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		WO 01/54736 A2	The Regents of the University of California	08-02-2001		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s publisher, city and/or country where published.		T <sup>2</sup>		
		SUPATTAPONE et al., "Elimination of prions by branched polyamines and implications for therapeutics" <i>PNAS</i> 96(25):14529-14534 (December 7, 1999)			

Examiner Date Signature Considered			
Signature Considered	Examiner	Date	
		 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.